Share on StockTwits

NPS Pharmaceuticals (NASDAQ:NPSP)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Friday.

Several other analysts have also recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday. They set an “outperform” rating and a $34.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of NPS Pharmaceuticals in a research note on Thursday, August 7th. They now have a $26.00 price target on the stock, up previously from $25.00. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. NPS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $39.23.

NPS Pharmaceuticals (NASDAQ:NPSP) traded down 1.62% during mid-day trading on Friday, hitting $26.73. 548,273 shares of the company’s stock traded hands. NPS Pharmaceuticals has a 52-week low of $21.60 and a 52-week high of $39.68. The stock’s 50-day moving average is $29.64 and its 200-day moving average is $30.71. The company has a market cap of $2.848 billion and a P/E ratio of 1358.50.

NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter. The company had revenue of $56.10 million for the quarter, compared to the consensus estimate of $53.06 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 53.7% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $0.02 earnings per share for the current fiscal year.

NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.